Mint Explainer: Why do Indian drug makers challenge global giants' patents?

Core Viewpoint - Indian courts maintain a strict yet balanced approach to pharmaceutical patents, focusing on preventing evergreening while safeguarding genuine innovation [1] Group 1: Legal Framework - The approach was established in the 2013 Novartis-Glivec ruling, where Novartis AG's patent application for the cancer drug Glivec was rejected [1] - The rejection was based on the failure to demonstrate proven therapeutic improvement over existing treatments [1] - The Supreme Court upheld the decision, reinforcing the scrutiny applied to drug patents in India [1]